SeaStar Medical Holding Corporation (ICU) Earnings Call Transcript & Summary
May 14, 2025
Earnings Call Speaker Segments
Eric Schlorff
executiveHi, thanks Jackie, and I appreciate everyone being here with us today. We've achieved significant strides on multiple fronts. Only a week ago, we brought on board yet another highly regarded children's hospital with national recognition as a QUELIMMUNE client, and we hit 50% enrollment in the NEUTRALIZE-AKI study; we received two additional breakthrough device designations from the FDA, which broadens our pipeline indications to tackle the harmful hyperinflammation that may arise in adult and pediatric cardiac surgery. We're particularly happy to observe growing uptake of our QUELIMMUNE treatment at our current customer locations. This resulted in a fourfold rise in our first quarter revenue versus the fourth quarter of 2024. Tim will soon go over our approach to commercializing QUELIMMUNE, but let me simply emphasize that our main objective for this year is to expand our customer base. We're obviously noticing that after adoption, customers are seeing outcomes that spare organs and save lives when they use the QUELIMMUNE treatment for their pediatric AKI patients. As we expand our customer base, we think we can generate substantial revenue from this modest yet vital market of roughly 4,000 patients each year in the United States. Now, shifting to what we consider the major upside potential for SeaStar Medical, I want to discuss the adult AKI market along with the other possibilities for the SCD treatment. Our clinical work is now aimed at breaking into the adult markets. It's crucial to understand that our SCD treatment is created as a disease-modifying approach that neutralizes hyperactive immune cells and halts the harmful hyperinflammation that disables vital organ function and ends lives. A severe instance of this was COVID-19, yet annually, millions of patients undergo surgery, trauma, or infection where their immune system goes into overdrive and a cytokine storm produces harmful hyperinflammation and sets off a chain of events that cause chaos in the patient's body. Our initial chance in the adult patient group is for managing hyperinflammation in patients with acute kidney injury or AKI who need continuous renal replacement therapy or CRRT; this is a comparable condition to pediatric AKI that threatens life with no viable treatment choices, yet it's a much bigger market prospect with more than 200,000 adults or 50 times the count of pediatric patients dealing with this condition. According to our present projections, this amounts to roughly a $4.5 billion total yearly market potential in the United States. Our NEUTRALIZE-AKI study for adult patients with AKI and CRRT is progressing well, and if everything proceeds as expected, we plan to submit a PMA for this indication in 2026. We shared yesterday that our continuing NEUTRALIZE-AKI study has achieved the 50% enrollment goal; this enrollment landmark also set off the pre-specified interim analysis by the trial's independent Data and Safety Monitoring Board, or DSMB. I'll have Kevin explain the specifics, but the interim analysis is intended to assess the safety and powering assumptions for the study. We expect that the DSMB will communicate its results to the company in the third quarter of 2025. I want to stress that we can't disclose any specific figures from the interim analysis, since doing so would compromise the trial's integrity. What we will do is put out a press release sharing the DSMB's final recommendation. For us, getting the NEUTRALIZE-AKI trial finished and possibly securing approval are important near-term milestones. This market opportunity has us quite enthusiastic, and on the medical affairs side we're already talking with physicians and healthcare providers to teach them about the SCD therapy and the data backing its use as a possible treatment for patients with AKI and CRRT. In addition to the AKI market, the SCD therapy has received breakthrough device designations for five other indications. Tim will walk through the potential commercial opportunities we hope to gain from our rich pipeline of indications. So, as an overview, I'll hand the call to Tim so he can discuss our commercial achievements and market opportunities.
Tim Varacek
executiveThank you, Eric, and I appreciate all of you being here for the SeaStar Medical call. It's exciting for us to share the strong revenue growth we saw in Q1, and the numbers behind that growth matter most to us. As physicians become more comfortable treating pediatric patients thanks to their experience with QUELIMMUNE therapy, we keep receiving repeat orders from our current sites. Beyond the 2 new customers we told you about earlier in the year, we shared today that QUELIMMUNE therapy has now been shipped to an additional new customer — a children's medical facility recognized nationwide. Our list of prospective customers keeps growing, and we expect to add multiple new sites before the year is over. For life-threatening acute kidney injury caused by sepsis or a septic-like condition in critically ill pediatric patients, QUELIMMUNE is the sole FDA-approved product. According to the data, these young patients face a 50% chance of surviving, and in many instances we've observed, the odds are even lower. For those who do survive, a substantial share also suffer lasting organ damage and need outpatient renal replacement therapy 2 to 3 times per week. That's what's also called dialysis. Significant improvement in these outcomes has been shown in our QUELIMMUNE clinical trial, so we believe that as time goes on, we can claim a healthy share of what we estimate as roughly a $100 million total annual U.S. market opportunity, calculated from a pediatric AKI population of approximately 4,000 patients. Turning now to our broader commercial strategy and current plans, site adoptions are our main objective. Today, our particular focus is on chosen children's medical facilities that generally handle a greater volume of these pediatric AKI patients. To give you a sense of scale, this market is highly concentrated, and we aim to concentrate on the top 50 pediatric sites across the U.S. that possess the resources needed to back this registry. As we've mentioned before, adoption at these medical centers can take a long time for any new device, and in the case of QUELIMMUNE, FDA approval mandates a post-approval surveillance registry, which adds another step and calls for a separate IRB approval of that registry. That generally requires more time, and it comes down to time to activation, which may range anywhere from several months up to approximately 8 months. Fortunately, we are in discussions with the majority of the leading pediatric medical centers in the U.S., and they genuinely want to bring QUELIMMUNE into their facilities; from the pediatric nephrology and ICU teams, we witness a strong dedication to championing this effort as we move through the adoption process alongside them. Based on our internal tracking so far, 7 out of every 10 pediatric hospitals we contact to assess interest end up committing to adoption of QUELIMMUNE therapy. Until more pediatric hospitals are activated and we can better understand the cadence of patient presentation within those hospitals, we still expect sales to be lumpy. The pediatric community's enthusiasm keeps building for what QUELIMMUNE therapy is able to achieve, and nothing validates wider uptake of QUELIMMUNE better than hearing about it from peers. Having laid out that context for our launch work on QUELIMMUNE, I want to move on to the commercial prospects for our SCD therapy platform. Because NEUTRALIZE- AKI is now well along, we've started pre-commercialization work to prepare for a possible launch of the SCD therapy as a treatment for adult patients with AKI requiring CRRT. As things stand, we expect to launch in adult AKI during Q4 of 2026, contingent on favorable clinical trial data and FDA approval. In the U.S., the overall market is roughly 50 times bigger than the pediatric population — approximately 200,000 patients each year who confront organ failure and possibly death, with nothing FDA-approved beyond the existing standard of care, namely CRRT and antibiotics. Given the revenue per patient we currently project, that works out to a total market opportunity of roughly $4.5 billion. For SeaStar Medical, even modest penetration of that market would mean substantial revenue. For this near-term potential market, we're also assuming a faster path to adoption than we saw with QUELIMMUNE, since the clinical need is greater given how large this population is, and since we can draw on pediatric customers' experience with QUELIMMUNE. Kevin and the medical affairs team are already conducting educational efforts in peer-to-peer settings, and we're eager about the possibility of offering this potentially life-saving therapy to adult patients with AKI and CRRT. Now, zooming out to the broader market, the adult AKI indication represents only the start of a long series of indications that may come after it. If we look solely at the indications for which FDA breakthrough device designation has been granted to us, we estimate that within the U.S. Market by itself, the total annual market size amounts to hundreds of thousands of patients who presently lack approved therapies for conditions in which destructive hyperinflammation produces critical care issues, organ failure, and death. Here at SeaStar Medical, we're dedicated to delivering our first and only SCD therapy to patients who right now confront lifelong organ damage and loss of life. With that, I'll hand the presentation to our Chief Medical Officer, Kevin Chung. Kevin.
Kevin Chung
executiveAppreciate that, Tim, and thank you to everyone on the call for being with us. I'm happy to share that enrollment in our NEUTRALIZE-AKI trial has passed the midpoint on the way to our target of 200 patients. As of Tuesday, we have 100 patients enrolled. As a lot of you are aware, NEUTRALIZE-AKI is our randomized control pivotal study, and it's built to find out whether as many as 10 sequential 24-hour treatments using SCD therapy can boost 90-day survival or recovery from kidney failure among patients with AKI who require CRRT, measured against CRRT by itself. We aim to enroll 200 patients in total, with the primary endpoint defined as the composite of mortality or dialysis dependency at 90 days. Hitting the 100th patient milestone sets off an interim analysis that the DSMB will carry out. That analysis gets underway after our 100th patient has hit the 90-day primary endpoint. Allowing a bit of extra time for the data and the review, we expect the DSMB to deliver its recommendation to the company during the third quarter of 2025. To give you a feel for how the analysis will unfold, the pooled data will be examined according to outcome differences between those who received treatment and the controls. The DSMB will hand SeaStar Medical and the NEUTRALIZE-AKI investigators a recommendation on how the trial should move forward. Though we can't know for sure what the independent DSMB will recommend, we built the interim analysis so the trial is properly powered. As Eric said, we have to protect the integrity of the trial. To keep expectations where they should be, we will share only the DSMB's summary decision and nothing else from the clinical results. Here are the possible DSMB recommendations: carry on with the trial as planned to a total of 200, which is what we expect. Raise the total sample size so there's adequate power if the effect size looks smaller than we anticipated. Halt the trial for overwhelming efficacy. Or, finally, halt the trial for futility. We anticipate a fully objective and unbiased recommendation from the DSMB, grounded in what the interim data reveals; now that we're at the halfway mark, we intend to redouble our efforts to reach our goal of 200 as fast as humanly possible. Because of that, we plan to bring additional sites online so we're screening as many patients as needed. I want to stress that, per trial design, we're concentrating enrollment on the right kind of patient through something called enrichment. There are particular patient groups, for instance, that have no modifiable disease whatsoever. Put another way, they would live or die no matter the intervention, given their underlying problem. Numerous pivotal studies in the past have failed, becoming victims of having too many of these kinds of patients; that won't happen to us. Although this trial's enrollment pace has, at moments, been painfully sluggish—such as during the month just passed—I want everyone to know that our staff is fully committed, at 100%, to finishing enrollment before this year ends. Furthermore, I have no doubt that the patients entering our study are the appropriate kind, and that we are properly screening out anyone whose disease cannot be modified in any way. Our chances for a successful trial, I know, have been maximized. Then, past the interim analysis: after the trial concludes and we reach 100% data lock, our plan is to move quickly in analyzing and reporting the data to the international medical community. If our primary endpoint is met, we intend to finish our PMA filing and deliver it to the FDA. Because we hold breakthrough device designation for adult AKI, communication with the FDA ought to be expedited throughout review and approval, so we would anticipate having product ready for patients at some point in Q4 of 2026. Today, NEUTRALIZE-AKI is unmistakably where our attention lies. Yet as a company, our strategic aim is to expand the addressable market fast, targeting other serious unmet medical needs in treating destructive hyperinflammation via further clinical trials. Outside of the adult AKI indication, we have received breakthrough device designation for five more, among them treating cardiorenal syndrome patients, hepatorenal syndrome patients, end-stage renal disease patients, and adult as well as pediatric cardiac surgery patients. Since our therapy is agnostic to organ and disease, additional indications lie ahead. Our opportunity to spare organs and save lives in these populations, we believe, starts with AKI. That summarizes our clinical development work and objectives, so I'll hand the call to our CFO, David Green.
David Green
executiveThanks, Kevin, and I appreciate everyone being here today. I'm going to walk through the financial results for our first quarter, then wrap up with a few expectations regarding the rest of 2025. To begin with a bit of housekeeping: our Form 10-Q is going to be submitted to the SEC sometime in the coming 24 hours. It's available on seastarmedical.com or through SEC.gov. Before getting into the quarter's financials, I also want to mention that what we've accomplished so far in 2025 includes several significant milestones for the business. As I mentioned during our year-end call, the things we achieved in 2024 and continuing into 2025 have put SeaStar Medical in a position to expand upon the initial two quarters of commercial revenue for QUELIMMUNE and to advance the NEUTRALIZE-AKI pivotal trial. Since that time, we've moved forward well on our priorities, which we described in today's press release. To call out three Q1 achievements: we saw stronger adoption of QUELIMMUNE among existing customers, and that produced higher revenue during the first quarter. We advanced the NEUTRALIZE-AKI pivotal trial in adult AKI patients, getting to the 50% enrollment milestone, and we controlled our resources during the quarter, which brought about reduced sequential operating expenses. We also bolstered our balance sheet by bringing in new capital and kept up our habit of watching spending closely. Now I'll move on to our first quarter 2025 financial results. We posted our largest quarterly revenue so far, delivering a four-fold rise in net revenue from sales of QUELIMMUNE therapy. First quarter 2025 revenue came in at $293,000, versus roughly $68,000 during the fourth quarter of 2024 and $0 in the same quarter a year earlier. As we said last quarter, we expect sales to be lumpy during this early launch period, though we anticipate an overall upward trend in revenue as current customers increase their use of QUELIMMUNE and as the overall count of hospitals buying QUELIMMUNE therapy grows. To add some detail around the Q1 revenue figure, we're happy that every existing customer made purchases of QUELIMMUNE during the quarter. As Tim mentioned, we feel quite optimistic about additional hospitals becoming customers in 2025, which means more children will have access to our life-saving therapy. Turning to cost of goods sold, our Q1 financial statements show no cost of goods sold. That aligns with GAAP and stems from sales of QUELIMMUNE units that had already been recorded as research and development expense. Once we build and subsequently sell new inventory as a commercial operation, we'll record cost of goods sold that matches sales from inventory. Relatedly, you might have observed that we reported an inventory balance for the first time on our March 31 balance sheet. We expect Q2 to be a transitional quarter as we start recognizing COGS. Operating expenses rose slightly to $4.1 million in the first quarter of 2025, compared with $3.9 million in Q1 of 2024. This shift mostly came from higher outlays tied to our commercial launch, along with rising enrollment in the NEUTRALIZE-AKI trial, though those increases were partly offset by lower G&A costs stemming from fewer accounting-related expenses as well as cuts to legal and consulting spending. On top of that, our net loss for the first quarter of 2025 narrowed to $3.7 million, versus a loss of $12.7 million in Q1 of 2024. We closed out the quarter holding roughly $5.3 million in cash. Going forward, our resources will be directed toward three top priorities. First, acquiring new customers for QUELIMMUNE. Second, finishing the NEUTRALIZE-AKI pivotal trial. Third, getting ready to submit a PMA once the adult AKI pivotal trial wraps up. To close, as we push these strategic objectives ahead, we anticipate that forward momentum will carry on as we deliver our life-saving SCD therapy to additional patients and clinicians, and as a growing number of investors recognize the sizable market opportunity taking shape for our SCD therapy. With that, I'll turn the call back over to Eric.
Eric Schlorff
executiveOkay, thank you, Dave. What we aimed to accomplish today with this initial quarterly earnings call was give all of you an overview of how far we've come, along with a lucid explanation of why we think SeaStar Medical's upcoming possibilities are so meaningful; it's our intention to keep holding these calls every quarter. Beyond that, we're connecting with a wider set of investors via a range of media channels, and we intend to arrange fireside chats whenever we have educational material to offer regarding SeaStar Medical; we feel strongly about what we can do in delivering a therapy that saves lives to critically ill individuals who right now lack any other option for quelling the cytokine storm brought on by an immune system that has become overactive. Once enrollment in the NEUTRALIZE-AKI pivotal trial is finished, we're eager to share the findings. Should those data prove favorable, our plan is to submit a PMA during 2026. Assuming it gets approved, we think there's a major chance to claim a considerable share of the adult AKI market. Put simply, we believe we keep building substantial worth for our investors and stakeholders, and we'll be aiming to narrow what appears to us as a large disparity between our present market cap and the prospects we foresee for our business. Having said that, I'll turn it over to the operator so questions can begin. Operator?
Nick Sherwood
analystHi there, good evening. Could you share the number of sites that have been activated so far for the adult clinical trial?
Eric Schlorff
executiveSure, hi Nick, appreciate it. Kevin, would you like to handle that question?
Kevin Chung
executiveRight, at the moment we've got 15 that are activated, and there are likely five more we intend to bring online within the coming three months.
Nick Sherwood
analystAll right, how many pediatric hospitals do you currently have as customers in total?
Eric Schlorff
executiveSure, Tim, would you like to handle that one?
Tim Varacek
executiveYes. There are 6 locations where commercial activity is underway, and several additional ones are advancing through the IRB process.
Nick Sherwood
analystAll right. So, regarding that IRB process and the pipeline, what kind of pipeline expansion have you observed during the first quarter versus the fourth quarter? Would you say that — revenues climbed enormously on a sequential basis this quarter, right? Is word of mouth playing a big role, where you're seeing that pipeline genuinely begin to speed up in this first quarter?
Tim Varacek
executiveYes, it's several factors combined. Thanks for asking, incidentally. Multiple elements are at play here. It comes down to the familiarity that sites already have. These sites can communicate with one another and exchange what they've learned, and when they use QUELIMMUNE therapy, they're seeing a difference. Word of mouth is certainly one piece of it, though we also proactively reach out to these hospitals. We make contact and have conversations with them, and very often, they show strong interest in eventually bringing in QUELIMMUNE therapy; the remaining piece is simply an operational matter. Depending on which type of hospital it is and what resources are available, that essentially indicates how long the timeline will be. In certain cases it's straightforward and happens rather fast, while in others it takes somewhat more time. Interest among these institutions in QUELIMMUNE therapy — and in what this therapy's potential means for these patients battling pediatric AKI — is abundant.
Nick Sherwood
analystYep, that's completely logical, and thanks for walking through it. Moving to a different topic — the fresh breakthrough designations. Could you explain what these two extra ones mean in terms of significance, and also how you decide which regulatory pathways get priority? With that many designations in play, I'd assume you can't afford to stretch your team too thin.
Eric Schlorff
executiveRight. Nick, Kevin, maybe you start by covering the clinical gap that exists for patients undergoing cardiac surgery, and I'll handle the rest of what he asked.
Kevin Chung
executiveYes, and I appreciate you raising that, Nick. Among the biggest expenses that hospitals across this nation face is cardiac surgery. A piece in Newsweek published just today underscored that point strongly. One contributing factor is that a fairly large share of these patients develop a complication leading to AKI. Consequently, among both adults and pediatric patients, we see this as an enormous area of opportunity where we could significantly improve outcomes. Why go through an extremely demanding cardiac operation tied to so many days spent in the hospital if the patient cannot survive and faces a complication that leaves them dependent on hemodialysis? Our goal is to stop that from happening. To properly examine this, more clinical trials will be necessary. With the adult launch underway, we're hopeful that grant funding and non-diluted funding will support some of those trials. Many of these centers have strong interest in using the SCD with their patient population; we also expect investigator-initiated studies to emerge. A mix of these efforts will propel our push toward securing approval of this device for that particular group of patients. I should note that even with an approval for AKI by itself, adoption will occur among those kinds of patients. We'll already be watching data come in gradually, even with only the AKI indication.
Eric Schlorff
executiveYes, and I'd like to build on Kevin's point. The teams in commercial and medical affairs are putting in serious effort to evaluate the market demand and penetration patterns across the 5 extra indications that carry these breakthrough device designations. Since the SCD therapy doesn't target specific disease states, and given that our first adult offering will be sold into the critical care market, it makes sense that we could readily introduce new indications there and market products to those very same buyers within those very same ICU units. So the chance to grow our product portfolio quickly is something we're genuinely thrilled about, as we mentioned during the prepared remarks.
Nick Sherwood
analystAll right, that level of detail is helpful. It seems that after you secure this initial adult approval, later ones should proceed much faster, simply because you'll have plenty of real-world data available and you've already gone through this once.
Kevin Chung
executiveExactly.
Eric Schlorff
executiveYeah, each one of these — yeah, go ahead.
Kevin Chung
executiveYes, definitely. So, a key area we're focusing on in the AKI pivotal trial is safety. Once the safety concern has been resolved and we have data for those particular other populations, our view is that things will become progressively simpler and the floodgates will open.
Nick Sherwood
analystAll right. That's great. I appreciate your taking the time to address everything I asked, and I'll get back in line.
Kevin Chung
executiveAppreciate it, Nick.
Operator
operatorThat wraps up the call for today, everyone. We appreciate each of you for being with us. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete SeaStar Medical Holding Corporation transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to SeaStar Medical Holding Corporation earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in SeaStar Medical Holding Corporation or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.